Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS: Dupilumab in uncontrolled moderate-to-severe asthma to prevent lung function decline
CTR20244206Phase 4Active
- Sponsor
- Sanofi
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in asthma, sponsored by Sanofi. Started Jan 2025; status: active.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20244206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244206.